Experiences with

Jaypirca

Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis (acalabrutinib/Calquence, ibrutinib/Imbruvica and zanubrutinib/Brukinsa) and non-covalent BTKi pirtobrutinib/Jaypirca.

Anybody have experience with jaypirca drug? Been told from pharmacist that is has lower risk for heart issues/atrial fibrillation than calquence but higher secondary cancer risks. Can anybody verify/share more?

From MedPage Today's ASH 2024 coverage (registration needed) of the international BRUIN CLL-321 Phase III randomized trial with 238 patients, with my emphasis; https://www.medpagetoday.com/meetingcoverage/ashhematology/113337 [i]Pirtobrutinib (Jaypirca) delayed disease progression versus other available

In a subgroup analysis of the BRUIN study -- which led to last year's approval of pirtobrutinib (Jaypirca) in CLL/SLL -- half of patients with Richter transformation responded to the oral non-covalent BTK inhibitor.

Pirtobrutinib (Jaypirca) /LOXO-305 (non-covalent) (First Non-covalent approved) https://cllsociety.org/2023/12/pirtobrutinib-is-the-first-reversible-btki-approved-in-cll-sll/ Works on patients with acquired resistance to available BTKis and venetoclax Starting at the 50 mg QD dose, Pirtobrutinib